$NVAX The India delay news is only RUMOR at this point. "The approval to launch Covovax — India's version of US firm Novavax's Covid-19 vaccine candidate — may take longer than expected. In the absence of its approval in the US, India’s drug regulator has asked for the immunogenicity data from Serum Institute of India (SII). While the trials are ongoing, data is likely to be submitted only by next month, people in the know told ET." People in the know. Lolololol! Read more at: economictimes.indiatimes.co...